INTRODUCTION: To determine the impact of physiologic doses of hydrocortisone on neurologic outcome after traumatic brain injury (TBI). METHODS: We conducted a retrospective study in a neurocritical care unit at a university teaching hospital. We included 29 patients with moderate and severe TBI requiring vasoactive drugs to maintain adequate arterial blood pressure who received corticosteroid. Infected patients were excluded. Blood cortisol levels were measured before and 30 and 60 minutes after the administration of a high-dose corticotropin stimulation test (HDST). Patients received hydrocortisone replacement therapy (200-300 mg/day) and vasoactive drugs requirements were noted. Intracranial pressure was managed according to a predefined protocol. RESULTS: A total of 14 out of 29 (48%) of patients were classified as responders to hydrocortisone (stopping vasoactive drugs within 3 days of starting hydrocortisone). The Glasgow Outcome Score (GOS) was used to assess neurologic outcome at 6 months. A favorable outcome (GOS 4 and 5) was observed in 11 out of 14 (79%) of responders and five out of 15 (33%) of nonresponders (p = 0.03). Of the responders, 12 out of 14 (85%) had a baseline cortisol below 414 nmol/L, and five out of 14 (36%) had primary adrenal insufficiency (AI) (primary AI: low baseline cortisol, and poor response to the HDST). Age, severity of injury, and response to hydrocortisone were predictive of outcome in multiple logistic regression analysis. CONCLUSIONS: Adrenal insufficiency is frequent after TBI, and hydrocortisone replacement therapy seems to be associated with a favorable neurologic outcome.
INTRODUCTION: To determine the impact of physiologic doses of hydrocortisone on neurologic outcome after traumatic brain injury (TBI). METHODS: We conducted a retrospective study in a neurocritical care unit at a university teaching hospital. We included 29 patients with moderate and severe TBI requiring vasoactive drugs to maintain adequate arterial blood pressure who received corticosteroid. Infected patients were excluded. Blood cortisol levels were measured before and 30 and 60 minutes after the administration of a high-dose corticotropin stimulation test (HDST). Patients received hydrocortisone replacement therapy (200-300 mg/day) and vasoactive drugs requirements were noted. Intracranial pressure was managed according to a predefined protocol. RESULTS: A total of 14 out of 29 (48%) of patients were classified as responders to hydrocortisone (stopping vasoactive drugs within 3 days of starting hydrocortisone). The Glasgow Outcome Score (GOS) was used to assess neurologic outcome at 6 months. A favorable outcome (GOS 4 and 5) was observed in 11 out of 14 (79%) of responders and five out of 15 (33%) of nonresponders (p = 0.03). Of the responders, 12 out of 14 (85%) had a baseline cortisol below 414 nmol/L, and five out of 14 (36%) had primary adrenal insufficiency (AI) (primary AI: low baseline cortisol, and poor response to the HDST). Age, severity of injury, and response to hydrocortisone were predictive of outcome in multiple logistic regression analysis. CONCLUSIONS: Adrenal insufficiency is frequent after TBI, and hydrocortisone replacement therapy seems to be associated with a favorable neurologic outcome.
Authors: Pejman Cohan; Christina Wang; David L McArthur; Shon W Cook; Joshua R Dusick; Bob Armin; Ronald Swerdloff; Paul Vespa; Jan Paul Muizelaar; Henry Gill Cryer; Peter D Christenson; Daniel F Kelly Journal: Crit Care Med Date: 2005-10 Impact factor: 7.598
Authors: Ian Roberts; David Yates; Peter Sandercock; Barbara Farrell; Jonathan Wasserberg; Gabrielle Lomas; Rowland Cottingham; Petr Svoboda; Nigel Brayley; Guy Mazairac; Véronique Laloë; Angeles Muñoz-Sánchez; Miguel Arango; Bennie Hartzenberg; Hussein Khamis; Surakrant Yutthakasemsunt; Edward Komolafe; Fatos Olldashi; Yadram Yadav; Francisco Murillo-Cabezas; Haleema Shakur; Phil Edwards Journal: Lancet Date: 2004 Oct 9-15 Impact factor: 79.321
Authors: R S Wijesurendra; F Bernard; J Outtrim; B Maiya; S Joshi; P J Hutchinson; D J Halsall; D K Menon Journal: Neurocrit Care Date: 2009-04-29 Impact factor: 3.210
Authors: Juan A Llompart-Pou; Joan M Raurich; Jon Pérez-Bárcena; Antonia Barceló; Jordi Ibáñez; José I Ayestarán Journal: Neurocrit Care Date: 2008 Impact factor: 3.210